FT819 Updated Nov 13
The next major catalyst for FT819 is the Phase 2 RECLAIM-LN interim data expected in H2 2027. Positive data would validate the registrational trial and could drive significant upside for this single-asset-focused biotech. Negative or mixed data would be bearish. The stock trades at $1.26 with a 52-week range of $0.95-3.23. The newly effective $100M ATM facility signals potential near-term dilution risk.
- FT819 is the first-ever iPSC-derived off-the-shelf CAR T-cell therapy, offering scalable manufacturing versus individualized autologous CAR-T. Phase 1 data across 36 patients in four autoimmune indications showed no dose-limiting toxicities, with 100% renal response at Month 6 in lupus nephritis patients. A Phase 2 potentially registrational trial (RECLAIM-LN) is underway with the first patient dosed in August 2026, supported by a $15M CIRM CLIN2 grant. Analyst consensus is bullish with a mean price target of $5.72 (327% upside) and 11 Buy/Strong Buy ratings.